EBV is associated with a broad range of malignancies. Adoptive immunotherapy of these tumors with EBV-specific CTL proved useful. We generated a panel of primary human T cells specific to various EBV antigens (i.e. Epstein-Barr nuclear antigen 3A, 3B and BamHI-M leftward reading frame) via transfer of modified TCR genes that are either coupled to CD3f or Fc(e)RIc. TCR-transduced T cells from 20-60% of donors (total number of 25) demonstrated specific lysis of EBV peptide-loaded target cells, whereas lymphoblastoid cell lines expressing native EBV antigens were not killed by any of the EBV-specific T cell populations. This non-responsiveness, confirmed at the level of nuclear factor of activated T cells activation, is not due to receptor configuration since identical receptor formats specific for melanoma antigens successfully re-targeted T cells to native melanoma cells. In an effort to generate a more potent receptor, we introduced a CD28 domain into one of the EBV-specific TCR. This TCR did not affect the cytotoxic response of re-targeted T cells, but dramatically enhanced antigenspecific IFNc production. We therefore conclude that these novel CD28-containing EBV-specific TCRs provide a basis for further development of TCR gene transfer to treat EBV-induced diseases.
Introduction
EBV is a gamma-1 B-lymphotropic herpesvirus found in all human populations, with a prevalence of over 90% in adults, and it typically persists in its natural hosts for life. B cells constitute the long-term reservoir for the virus, whilst the oropharyngeal epithelium is the site for periodical virus replication. Important to the immune control of EBV are EBV-specific CTLs. In healthy individuals, EBV-specific CTL recognize MHC class I-restricted latent and lytic viral antigens, and are thought to prevent virus spreading (1, 2) . Only a small subset of at least 11 viral genes is expressed in latently infected B cells and recognized by EBV-specific CTL. Latent viral gene products can be divided into three groups: (i) the EBVencoded RNAs (EBERs) 1 and 2; (ii) the EBV nuclear antigens Epstein-Barr nuclear antigen (EBNA) 1, 2, 3A, 3B, 3C and EBNA-LP and (iii) the latent membrane proteins (LMP)-1, 2A and 2B [reviewed in (3, 4) ]. EBV is associated with a broad range of malignancies of mostly hematopoietic or epithelial origin, which can be divided into the following types of latencies based on EBV gene expression patterns: type I latency expresses the EBER and EBNA-1 genes; type II latency expresses the EBER, EBNA-1 and the LMP genes; and type III latency expresses the EBER, all EBNA and LMP genes. These types of expression patterns are unique to various forms of tumors, such as (immunosuppression related) lymphomas in transplant recipients and patients with AIDS, gastric carcinomas and the Reed-Sternberg cells in Hodgkin's disease (5) (6) (7) (8) (9) (10) (11) .
Adoptive immunotherapy of EBV-positive tumors in allogeneic bone marrow transplant recipients with HLA-restricted, EBV-specific T cells has proven effective. This immunotherapy, when performed with non-selected lymphocytes from EBVseropositive bone marrow donors, is associated with graftversus-host disease (GVHD) (12, 13) . However, EBV-specific CTL generated in vitro by stimulation with autologous EBVtransformed B-lymphoblast cell lines (B-LCL) have clear antiviral effects without causing GVHD (14, 15) . Clinical responses were observed when patients with EBV-positive post-transplant lymphoproliferative disease were treated with either autologous or partly HLA-matched allogeneic CTL (15, 16) . Unfortunately, identification, isolation and expansion of tumor-specific T cells are laborious and time consuming and have not been successful in all patients (17) .
Alternatively, autologous T cells can be genetically programmed to express MHC-restricted antigen-specific receptors. Primary human T cells can be re-targeted to antigen-expressing cells by transfer of human TCRa/b genes. Successfully targeted MHC class I-restricted antigens range from melanoma cancer/testis antigens [i.e. MAGE-1/HLA-A1 (18, 19) ], melanocyte differentiation antigens [i.e. MART-1/HLA-A2 (20) or gp100/HLA-A2 (21) ] to viral antigens [i.e. HIV gag/HLA-A3 (22) , HIV pol/HLA-B35 (23) or EBV LMP2/HLA-A2 (24) ]. These re-targeted human T cells were shown not only to bind the relevant peptide/MHC ligand but also to produce cytokines and kill target cells upon antigen-specific stimulation.
The therapeutic use of full-length TCR genes, however, may face problems. The formation of newly formed TCRa/b heterodimers comprising both introduced and endogenous TCR chains may induce unknown and possibly dangerous specificities, and constitute a theoretical side effect of TCR gene transfer (18, 22, 25) . In addition, the introduction of TCRa/b transgenes into Tcells may result in a low and unstable surface expression of TCRa protein (26) . Moreover, TCRa/b 'mispairing' as described above dilutes the expression of the desired TCRa/b heterodimers. Indeed, we recently observed that only a fraction of T cells transduced with TCRa and b genes and expressing the introduced TCRb chain is able to bind the corresponding peptide/MHC tetramer (21), suggesting that the introduced and surface-expressed TCRb chain pairs with the endogenous TCRa chain. We have pioneered the use of modified two-chain (tc) and single-chain (sc) TCR molecules as an alternative to full-length TCR, and which addresses the above-mentioned issues (27) . Please note that the term-modified TCR is chosen deliberately to distinguish these receptors from chimeric TCRs, a term mostly covering classical (non-MHC restricted) antibody-based receptors that are used for gene transfer. The modified tcTCR-based receptors, that for instance comprise CD3 signaling molecules, i.e. CD3f, result in exclusive pairing between the introduced TCRa and b chains, and 'rescue' the surface expression of the introduced TCRa chain.
Here we studied whether the modified TCR approach is applicable to re-target primary human T cells to EBV antigenexpressing target cells. Such an approach would allow for an 'off-the-shelf' treatment regimen based on the ex vivo transduction and expansion of patient T cells with genes encoding for class I MHC-restricted and EBV-specific TCR.
Methods

Cells and reagents
Peripheral blood lymphocytes from healthy donors were isolated by centrifugation through Ficoll-Isopaque (density = 1.077 g cm ÿ3 ; Pharmacia Biotech, Uppsala, Sweden). Transduced primary human T cells, the EBV-specific CTL clones BK289 [specific for the HLA-A*1101-presented EBNA-3B peptide IVTDFSVIK (IVT/A11) (28, 29) ], A4.5 [specific for the HLA-A*0201-presented BamHI-M leftward reading frame (BMLF-1) peptide GLCTLVAML (GLC/A2) (30) ] and CF3 [specific for the HLA-B*0802-presented EBNA-3A peptide FLRGRAYGL (FLR/B8) (31) ] and the melanoma-specific CTL clone 82/30 (specific for the HLA-A*0101-presented melanoma peptide EADPTGHSY (EAD/A1)) were all cultured with RPMI 1640 medium supplemented with 25 mM Hepes, 200 nM L-glutamine, 10% human serum, 360 IU ml ÿ1 rIL-2 (Proleukin, Chiron, Amsterdam, The Netherlands) and the antibiotics streptomycin (100 lg ml ÿ1 ) and penicillin (100 U ml ÿ1 ). Cells were stimulated every 2 weeks with a mixture of irradiated allogeneic feeder cells, as described elsewhere (32 
Modification of EBV-specific TCR genes
Modified TCRs specific for EBV were constructed as follows. TCRa and b DNA was obtained by PCR using template cDNA from the CTL clones BK289 (which expresses the TCR genes Va1s1b/Ja45, Vb22s1/Jb2s1), A4.5 (Va15s1/Ja23, Vb4s1/ Jb1s4) and CF3 (Va2s1/Ja9s14, Vb8s6/Jb1s2). Two-chain TCRab linked to CD3f (tcTCRab:f) specific for EBNA-3B or BMLF-1 were constructed by linking the extracellular domains of the TCR a and b chain to the CD3f molecule (i.e. VaCaf and VbCbf) [as described in (18)]. A single-chain TCRab linked to Fc(e)RIc (scTCRab:c) specific for EBNA-3A was constructed by coupling the TCR Va and VbCb domains, interspersed by a flexible linker, to a few amino acids of the constant domain of the j light chain, the transmembrane domain of the CD4 molecule and the signaling domain of Fc(e)RIc (i.e. VaVbCbCjCD4c) [as described in (33)]. tcTCRab:f specific for the melanoma antigens MAGE-1 (18) or gp100 (34) were used as control receptors. Additionally, we generated EBNA-3B-specific TCRa and b chains containing CD28 (transmembrane and intracellular domains: aa 153-220 according to gi4557430) and CD3f (intracellular domain: aa 50-162 according to gi4557430). The CD28-CD3f DNA (kindly provided by H. Abken, Cologne, Germany) was re-amplified and put downstream of the variable and constant domains of the TCR DNA via BamHI and XhoI sites. Specific primer sequences to amplify the TCR and other domains will be given upon request. The modified TCR genes were subsequently cloned into the retroviral vector pBullet, as described elsewhere (18) .
Retroviral gene transduction of TCR into human T cells
Primary human T cells of healthy donors were depleted for cells endogenously expressing TCRVb22 and Vb4 by using anti-TCRVb22 and anti-TCRVb4 mAbs and goat anti-mouse Ig-labeled microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany) or magnetic beads (Dynal, Oslo, Norway). Following depletion, T cells were pre-activated with anti-CD3 mAb prior to retroviral transductions. The activated T cells as well as Jurkat T cells were transduced with pBullet retroviral vectors containing the TCR genes of interest. Supernatant containing retroviral vector was produced by the packaging cell line Phoenix. The transduction procedure used was optimized for human T cells and described by Lamers et al. (35) . In short, 24-well culture plates were coated with RetroNectin and pretreated with retroviral particles by centrifugation. Next, 10 6 human T cells were centrifuged in fresh retroviral supernatant, and cultured for 4-5 h at 37°C/5% CO 2 . T cells were allowed to recover in normal T cell medium overnight prior to a second transduction cycle, after which cells were harvested and transferred to T25 culture flasks. After sufficient numbers were obtained, TCR-transduced T cells were analyzed for receptor expression by flow cytometry.
Flow cytometric analysis of retrovirally transduced T cells
TCR-transduced T cells were analyzed for transgene expression by flow cytometry using PE-conjugated anti-TCR mAb (Vb22 or Vb4) or FLR-HLA-B8 tetramer complexes. Soluble FLR/HLA-B8 tetramers were made by incubating streptavidin-PE and biotinylated FLR/HLA-B8 monomers at a 1:4 molar ratio for 1 h at 4°C. For immunostaining, 0.25-0.5 3 10 6 transduced T cells were incubated with the mAbs or tetramers on ice for 30 min, washed, fixed (1% PMA) and analyzed on a flow cytometer (Becton Dickinson). TCR-transduced T cells were subsequently enriched via anti-TCRVb mAbs or FLR/ HLA-B8 tetramer and anti-PE MACS MicroBeads (Miltenyi Biotec) according to the manufacturer's instructions. In short, 10 3 10 6 cells were labeled with PE-conjugated antibody or tetramer for 30 min at 4°C, washed and re-suspended in 160 ll of degassed PBS containing 1% BSA and 2 mM EDTA (wash buffer). Magnetic anti-PE MicroBeads were added to the cells in a final volume of 200 ll, after which cells were incubated for 15 min at 4°C, washed and again re-suspended in wash buffer. Next, cells were loaded onto a pre-washed miniMACS column (MACS High Gradient Magnetic Separation Column MS, Miltenyi Biotec). PE-bound cells were washed several times and carefully collected in wash buffer by applying a plunger to the column. T cells enriched for the introduced TCR were expanded on feeder plates prior to experiments.
Cytotoxicity assay
Cytotoxic activity of CTL clones and TCR-transduced primary human T cells versus indicated target cells was assayed in a standard 6-h 51 Cr-release assay (36) . CTL clones and TCRtransduced T cells were co-cultivated with either peptidepulsed target cells or target cells expressing the native antigen of interest. Peptide loading was performed by the addition of the peptide (10 lM final) to the target cells prior to incubation with effector T cells. Specific blocking of cytolytic activity was studied by adding anti-MHC class I mAb or mIg (both at 10 lg ml ÿ1 final) to the target cells 15 min prior to co-cultivation with effector T cells.
Nuclear factor of activated T cells reporter gene assay
Nuclear factor of activated T cells (NFAT) reporter gene assays were performed as described elsewhere (34) . In short, exponentially growing TCR-transduced Jurkat T cells (5 3 10 6 ) were transiently transfected by electroporation with 5 lg of both the NFAT-luciferase (Stratagene, La Jolla, CA, USA) and b-galactosidase constructs. Twenty hours post-transfection, Jurkat T cells were transferred to round-bottom 96-well tissue culture-treated plates (Costar, Corning, NY, USA) at 2 3 10 5 cells per well and were stimulated for 6 h with anti-TCR mAbs, peptide-MHC complexes or target cells (at 10 5 cells per well) in RPMI 1640 medium supplemented with 1% BCS at 37°C/5% CO 2 . Cells were subsequently lysed and luciferase and bgalactosidase activities were determined. Luciferase activities were normalized on the basis of b-galactosidase activities and expressed relative to a non-stimulated condition (i.e. medium only: set to 1.0). Antibodies used to stimulate TCR-transduced Jurkat T cells comprise anti-TCRVb22, Vb8 mAb or mIg, precoated in 96-well plates at 0.1 lg per well. For stimulations with FLR-HLA-B8 complexes, biotinylated BSA (at 1 lg ml ÿ1 final) was pre-coated in 96-well plates (overnight at 4°C), after which wells were washed with PBS and streptavidin (10 lg ml ÿ1 ) was bound to the biotin for 45 min at room temperature. Plates were washed again and biotinylated FLR-HLA-B8 complexes (at indicated concentrations) were added to wells and incubated for 30 min at room temperature. Finally, for stimulations with target cells, CJO, T2-A11 cells and CFpuy cells were peptide Functional transfer of EBV-specific modified TCR 3 at Pennsylvania State University on February 23, 2013 http://intimm.oxfordjournals.org/ loaded for 30 min at 37°C/5% CO 2 with 10 lM of the relevant peptide prior to their use in NFAT reporter gene assays. As a positive control for NFAT activation, cells were stimulated with 10 ng ml ÿ1 PMA and 1 lM ionomycin for 6 h at 37°C/5% CO2.
IFNc and tumor necrosis factor a ELISA
To quantify secreted IFNc and tumor necrosis factor a (TNFa) by TCR-transduced human T cells after antigen-specific stimulation, 6 3 10 4 T cells were cultured in the presence of 3 3 10 4 EBV-expressing target cells with or without additional peptide for 18 h. As a positive control, transduced T cells were stimulated with PMA and ionomycin. Supernatants were harvested and levels of IFNc and TNFa were measured by standard ELISA according to the manufacturer's instructions (Central Laboratory for Blood Transfusions, Amsterdam, the Netherlands).
Results
Expression of EBV-specific TCR on transduced T cells
Primary human T cells and the human Jurkat T cell line E6.1 were retrovirally transduced with modified TCRs derived from various EBV-specific CTL clones. Transduced T cells were enriched for receptor-positive cells to obtain similarly high expression levels of the introduced TCR on both cell types. Surface expression levels of the TCR transgenes on primary human T cells were 88% [mean fluorescence intensity (MFI) on a scale of 1-10 4 relative linear channels, 440], 65% (MFI, 312) and 67% (MFI, 315) for the tcTCRab:f specific for EBNA-3B and BMLF-1 and the scTCRab:c specific for EBNA-3A, respectively (Fig. 1A) . Expression levels on Jurkat T cells were 55% (MFI, 450) and 59% (MFI, 290) for the tcTCRab:f specific for EBNA-3B and the scTCRab:c specific for EBNA-3A, respectively (Fig. 1B) . Jurkat T cells were co-transduced with the human CD8a gene (expression level 100%; MFI, 590). The frequency of CD8-positive T cells within the transduced primary human T cells was higher than 50% (data not shown). Mock-transduced T cells did not bind anti-TCRVb mAbs or tetramers specific for the introduced TCR (Fig. 1) .
Peptide-loaded target cells are specifically lysed by primary human T cells transduced with EBV-specific TCR Human T cells positive for EBV-specific TCR were first tested for their cytolytic reactivity versus target cells loaded with EBVpeptides. For pulsing experiments with peptides derived from the latent viral proteins EBNA-3A and B, we chose target cells that do not natively present the corresponding EBV-epitope, i.e. the B-LCL HAR (HLA-B8 positive) and T2-A11 cells, respectively. For loading experiments with the lytic cycle protein-derived BMLF-1 peptide, we used the B-LCL BSM and T2 cells (both HLA-A2 positive) as target cells. Primary human T cells from 5 out of 9 (56%), 2 out of 6 (33%) and 2 out of 10 (20%) different donors transduced with the tcTCRab:f specific for EBNA-3B or BMLF-1 and the scTCRab:c specific for EBNA-3A, respectively, specifically lysed target cells that were loaded with 10 lM of the corresponding peptide. Target cells without peptide were not lysed (Table 1 and data not shown). A representative example of a cytotoxic response of TCRtransduced primary human T cells is shown in Fig. 2A (left  panel) . Primary human T cells of the same donor transduced with the MAGE-1/HLA-A1-specific tcTCRab:f (18), which served as a positive control, lysed MAGE-1 peptide-pulsed target cells (Fig. 2B) . Peptide-pulsed target cells were also cocultivated with the corresponding parental CTL clones (EBVas well as MAGE-1-specific CTLs) and in all cases target cells pulsed with the relevant peptide were specifically lysed, whereas target cells without peptide were not lysed (see Fig. 2A and B, right panels) . Mock-transduced T cells were not able to lyse any of the target cells. (Table 1) . Surprisingly, only exogenously peptide-loaded BK cells were lysed by the tcTCRab:f pos T cells, whereas BK cells without exogenously added peptide were not lysed (Fig. 3A) . (Table 1) . Again, only peptide-loaded target cells were lysed by scTCRab:c pos Tcells, whereas target cells without exogenous peptide were not lysed. Since there is no cell line available that natively expresses the epitope recognized by the BMLF-1-specific TCR, the tcTCRab:f pos T cells specific for this EBV-epitope have only been tested versus peptide-loaded target cells. Even at extremely high effector to target cell ratios (81:1), T cells positive for EBVspecific TCR were not able to lyse native targets (see Fig. 3A ). In contrast, primary human T cells of the same donor transduced with the MAGE-1/A1-specific control TCR did lyse target cells that expressed the natively processed MAGE-1 epitope without addition of exogenous peptide (Fig. 3B) . The parental CTL clones, including the EBV-specific ones, were also able to lyse target cells that express natively processed antigen ( Fig. 3A and B) . Again, mock-transduced T cells were not able to lyse any of the target cells tested.
Primary human T cells transduced with
Receptor-specific activation of NFAT via EBV-specific TCR in Jurkat T cells Fig. 4A and data not shown) . In contrast, we did demonstrate receptor-specific activation of NFAT in Jurkat T cells transduced with a melanoma gp100/A2-specific tcTCRab:f in response to not only anti-TCRVb mAb but also T2 cells pulsed with the gp100 peptide as well as native gp100 pos /A2 pos FM3 melanoma cells (Fig. 4B) . Non-transduced Jurkat T cells only showed NFAT activation upon stimulation with anti-TCRVb8 mAb (specific for the endogenous TCRb of Jurkat T cells), but not with anti-TCRVb22 mAb, anti-TCRVb14 mAb, FLR/HLA-B8 peptide-MHC complexes or target cells.
Incorporation of CD28 into EBV-specific TCR allows re-targeted T cells to respond to EBV antigen-expressing target cells
In an effort to improve genetic re-targeting of T cells to EBV antigen-expressing cells, we extended the observations obtained with CD28-containing antibody-based receptors (37) to TCR and generated EBNA-3B-specific TCR containing CD3f preceded by CD28 [two-chain TCRab linked to CD28 and CD3f (tcTCRab:28f)]. T cells expressing either tcTCRab:f or Average % (6SEM) of transduced primary human T cells expressing the mentioned markers.
d A cytotoxic T cell response is defined by the following criteria. Specific cytolytic activities versus antigen-positive target cells show a dose response over the E:T ratios tested, representing 3-fold dilutions of the target cells. Such specific activities are at least 25% and twice as high as the specific activities versus antigen-negative target cells at two or more consecutive E:T ratios. (Fig. 5) , whereas it dramatically increased the antigen-specific IFNc production (Fig. 6) . The antigen-specific production of TNFa was low and not affected by the inclusion of CD28. . Target cells were pre-incubated with peptide for 30 min at 37°C at a final concentration of 10 lM. The effector cell to target cell ratio is indicated in the figure. Data of one representative donor are shown. Antigen specificity was confirmed by blocking experiments as described in the legend to Fig. 2 (data not shown) . The parental CTL clones were used as positive controls. Mock-transduced primary human T cells were not cytolytic toward the above-mentioned target cells.
Discussion
This paper reports on the functional characterization of EBVspecific modified TCR that are considered promising tools to treat EBV-induced diseases following gene transfer into human T cells. We generated a panel of TCRs with specificities to various EBV antigens such as EBNA-3A, 3B and BMLF-1. Our analysis of the antigen reactivity and specificity of TCRtransduced human T cells demonstrated that EBV-specific TCR can mediate a cytolytic response versus peptide-loaded B-LCL but not native EBV pos target cells. Table 1 shows that 20 to about 60% of donors of which the T cells express the introduced TCR specifically lyse EBV-peptide-loaded target cells (see also Fig. 2 ). This MHC-restricted killing of target cells showed a clear dependence on the antigen specificity and type of modified TCR used, with the EBNA-3B-specific tcTCRab:f being the most effective TCR. The non-responsiveness toward B-LCL that express endogenously processed antigen (Table 1 and Fig. 3 ) was somewhat expected for T cells transduced with TCR specific for BMLF-1 since only a minor fraction of B-LCLs express EBV lytic proteins. However, EBNA-3A and B antigens are expressed by numerous B-LCLs, yet appear unable to initiate a cytotoxic response by T cells transduced with the relevant TCR. In fact, prolonging the duration of the cytotoxicity assay (from 6 up to 16 h) or measuring cytokine production (i.e. IFNc or TNFa) hardly resulted in detectable antigen-specific T cell responses versus antigen-positive target cells. Gene transfer or perhaps donor-related aspects as possible explanations for the absence of cytolysis of native targets by EBV-specific TCR pos T cells are highly unlikely since a melanoma-specific TCRab with an identical format, when introduced into T cells from the same donor, is clearly able to mediate the expected response versus native target cells (Fig. 3B) .
The Jurkat T cell-based NFAT reporter gene assay provides a fast and sensitive method to functionally validate TCRs (34) , and was used to monitor signaling events downstream of EBVspecific TCRs. NFAT activation data confirmed the cytotoxicity findings. Jurkat T cells expressing TCRs specific either for EBNA-3B or 3A activated NFAT after stimulation with antiTCRVb mAb and peptide-MHC complexes, but not following co-cultivation with antigen-positive target cells (Fig. 4A) . This is in contrast to melanoma-specific and similarly modified TCRab expressed on the same Jurkat T cell line, which did induce NFAT activation after stimulation with peptide-pulsed target cells as well as native antigen-positive melanoma cells (Fig. 4B ). These data demonstrate that EBV-specific TCRs are functional and are, at least following a strong TCR stimulus, able to initiate a signal transduction cascade ultimately leading to activation of NFAT. The ability of these EBV-specific modified TCR to initiate a signal was confirmed in primary human T cells in which CD3f phosphorylation was observed in response to strong TCR stimuli (data not shown).
We postulate the following explanations for the observed non-responsiveness of EBV-specific TCR-transduced T cells, or perhaps virus-specific TCR-transduced T cells in general.
First, the non-responsiveness may be inherent to a suboptimal balance between TCR density and antigen density. We have shown earlier that such a functional balance exists between receptor density on the one hand and tumor-antigen density on the other (25). Interestingly, the expression level of the introduced EBV-specific TCR was about 19% lower in T cells from donors lacking a cytotoxic T cell response against peptide-loaded target cells relative to T cells from donors showing a peptide response (25 TCR-transduced T cell populations tested in 48 experiments, Student's t-test: P < 0.006). In addition, intra-donor comparisons of T cells from responding donors showed that responses were only observed when T cells expressed a sufficiently high level of TCR (data not shown). These observations are in line with a study on T cells transduced with an HIV-specific TCR, and suggest that a high receptor density on transduced T cells compensates for low antigen density on target cells (22) . We speculate that the density of EBV antigen on in vitro cultured B-LCL target cells is too low to functionally interact with a bulk culture of human T cells transduced with EBV-specific TCR, whereas it is sufficiently high to trigger lysis by the original and highly differentiated EBV-specific CTL clones from which the DNA sequences coding for the TCR variable domains had been derived. Next to TCR expression, the surface expression of accessory and adhesion molecules such as CD2, CD3, CD11a/CD18, co-stimulatory molecules such as CD27 and CD28 as well as homing molecules such as CD62L also affect T cell responses in vitro (38, 39) . Differences in the expression levels of such T cell markers, especially in the context of low antigen expression, may further contribute to the observed EBV-specific T cell non-responsiveness.
Second, gene transduction and culture conditions may also adversely affect the reactivity of EBV-specific T cells. Transduction of primary human T cells with retrovirus produced by other packaging cells (i.e. 293T or PG13) had no effect on the observed non-responsiveness. It is of interest, however, to note that EBV-specific T cells are sensitive to activationinduced cell death during the first days of culture (such as after anti-CD3 mAb T cell pre-activation), and do not fully differentiate into terminal effector T cells (CD45RA + , CD27 ÿ , 
CCR7
ÿ ) during subsequent culture (40) . Cultured T cells, expressing either an endogenous or introduced EBV-specific TCR, may therefore show a hampered response to antigenpositive target cells. Choosing alternative recipient cells for TCR transduction, such as antigen-experienced virus-or allospecific T cells (41) (42) (43) , may benefit EBV-specific T cell retargeting. To this end, we have tried a small panel of different CTL clones and cell lines (CTL cell lines were kindly provided by D. H. Crawford, Edinburgh, UK) but experienced suboptimal TCR gene transfer efficiencies when compared with primary human T cells (data not shown). Highly differentiated T cells may be more resistant to gene transfer than primary T cells, which possibly impacts gene transfer of TCR more than that of scFv (41) because of the inherent low ligand-binding affinity of TCR when compared with scFv. The use of antigenexperienced primary T cells, pre-sorted from PBMC with virusspecific tetramers, is reported to allow functional TCR gene transfer (43) and may represent an attractive strategy to improve EBV-specific TCR gene transfer.
Third, the receptor's ligand-binding affinity and/or signaling capacity may simply be sub-optimal to mediate T cell responses toward EBV antigen-positive target cells. Studies on gene transfer of full-length (non-modified) TCRa and b chains specific for various viral antigens suggest that the success of TCR gene transfer is determined by the specific TCR used. For example and in line with our data, genetic introduction of TCR specific for EBV and HIV antigens has demonstrated clear T cell responses to peptide-loaded target cells but no responses to native antigen-positive cells other than virally super-infected cells (22, 24) or at most low responses to virus-infected target cells (23) , whereas gene transfer of TCR specific for Human Papillomavirus and Cytomegalovirus antigens has demonstrated clear T cell responses to either peptide-loaded target cells or virusexpressing target cells (44, 45) . Properties inherent to the specific TCRs, such as ligand-binding affinity and/or signaling capacity, may have contributed to the observed differences. In this respect, the incorporation of a CD28 domain in classical (non-MHC restricted) antibody-based receptors has already proven its surplus value for T cell re-targeting. scFv receptors harboring both CD28 (transmembrane plus intracellular domains) and either the Fc(e)RIc or CD3f chain (intracellular domains only) are clearly superior in their capacity to proliferate and mediate production of T h 1-type cytokines (but not cytotoxicity) when compared with identical receptors lacking CD28 (37, 46) . Primary mouse CD8+ T cells transduced with a CD28-containing scFv had a greater capacity to proliferate, secrete IFNc and inhibit established tumor growth and metastases in mice bearing tumors when compared with T cells transduced with an scFv lacking CD28 (46) . In fact, it is currently believed that antigen-specific IFNc secretion may represent a better in vitro measure than cytotoxicity to predict antitumor efficacy of T cells in vivo. Also primary human T cells expressing a CD28-containing scFv exerted significant and durable antitumor activity in SCID mice with a transplanted human tumor (47) . In the present study, we extended these observations to human TCR, and generated an EBNA-3B-specific tcTCRab:28f. This CD28-containing TCR did not result in enhanced cytotoxic responses toward antigenpositive target cells (Fig. 5) , but dramatically increased receptor-mediated IFNc (but not TNFa) production (Fig. 6) . The cytokine production appeared maximal in response to EBNA-3B-positive targets (CJO, Fig. 6 ; BK, not shown) and was not increased further due to peptide loading. This is the first report showing the functional relevance of human T cells genetically re-targeted with CD28-containing TCR, which, at least in this setting, confirms in vitro findings with CD28-containing antibody-based receptors (37) .
Taken together, this paper shows that the success of genetic re-targeting of primary human T cells, as a therapeutic tool to treat cancers or viral diseases, depends on the chosen target antigen and type of receptor used, and works well for melanoma-specific receptors but is limited for EBV-specific receptors. The inclusion of a CD28 co-stimulatory domain provides a receptor that mediates enhanced EBV antigenspecific responses (i.e. IFNc production) and represents a strategy that can be further developed to treat EBV-induced diseases with re-targeted T cells.
